Company Number: 13537400

Analysis Date: 2025-07-20 16:41 UTC

1. Risk Rating: MEDIUM
   Ensilicated Technologies Ltd exhibits characteristics typical of an early-stage biotechnology start-up: investment in fixed assets and R&D, combined with operating losses and reliance on investor support. While the company currently maintains healthy net current assets and cash reserves, the significant increase in short-term liabilities and worsening profit and loss reserves indicate some solvency and liquidity risk if investor support diminishes.

2. Key Concerns:

• Rising Current Liabilities: Current liabilities increased sharply from £10.9k in 2023 to £200.9k in 2024, primarily trade creditors and tax liabilities, which may pressure short-term liquidity.
• Accumulated Losses: The profit and loss account deficit widened from -£132.9k to -£415.3k, reflecting ongoing losses typical of a development-stage biotech but increasing financial strain.
• Investor Reliance for Going Concern: Directors explicitly state reliance on continued investor support for meeting obligations. Any disruption to funding could pose solvency challenges given the current operating losses.

3. Positive Indicators:

• Strong Net Current Assets: Despite the rise in liabilities, net current assets remain robust at £365.8k, supported by £363k cash and £203.7k trade debtors.
• Increasing Tangible Fixed Assets: Investment in plant and machinery rose, indicating ongoing commitment to product development and capacity building.
• Timely Compliance: No overdue filings for accounts or confirmation statements, reflecting good regulatory compliance and governance practices.
• Experienced Board: Presence of multiple directors with scientific and pharmaceutical backgrounds provides operational stability and strategic oversight.

4. Due Diligence Notes:

• Examine Trade Creditors Composition: Investigate the cause of the large increase in trade creditors and assess payment terms and potential supplier risks.
• Review Cash Flow Projections and Funding Plans: Confirm adequacy of cash runway and investor commitments beyond the next 12 months to support ongoing losses.
• Assess Revenue Generation and Commercialization Timeline: Clarify current revenue streams, if any, and expected timeline for product commercialization and break-even.
• Evaluate Related Party Transactions: Confirm any director loans or financial support and their terms to understand intra-group funding reliance.
• Confirm Accounting Treatment of R&D Costs and Grants: Ensure capitalization policies and government grants are appropriately accounted for and disclosed.

---